Why JNJ's Pullback Is a Buying Opportunity

Johnson & Johnson (JNJ) reported second-quarter earnings that beat expectations on both revenue and earnings. Revenue rose 6.8% year-over-year to $25.31 billion, 100 basis points above consensus. Adjusted EPS of $2.90 beat by a nickel, up 4.7% from last year.

The company also raised its full-year guidance, now expecting 7.3% top-line growth and adjusted EPS of $11.68, above analyst estimates. JNJ also generated $8.7 billion in free cash flow, supporting its balance sheet and dividend.

Despite the strong results, JNJ's stock pulled back about 2% following the release, extending a decline from its early-July highs. The stock is now down nearly 10% from its peak, which analysts view as a textbook entry point.

The pullback appears driven by profit-taking after a run-up ahead of earnings, rather than any fundamental weakness. Institutional investors, who own over 60% of the stock, have been accumulating shares.

JNJ's earnings confirm that the company has successfully navigated its patent cliff, with new drug approvals and pipeline advances driving growth. The company has received half a dozen new approvals and a dozen positive pipeline updates, including the OTTAVA robotic system expected to launch later this year.

The raised guidance and strong cash flow underscore JNJ's ability to sustain its dividend, which yields 2.1% and has grown at a mid-single-digit rate. For income investors, this pullback offers a chance to lock in a higher yield.

The planned spin-off of the orthopedics business is another catalyst, expected to unlock value by focusing on higher-margin pharma and medtech. Analysts see this as a price-multiple expansion opportunity.

Risks remain, including ongoing talc litigation, but the market views it as a manageable headwind rather than a company-ending threat. The patent cliff risk is largely mitigated.